Related Experiment Video
Updated: Jun 23, 2026
Generation of Natural Killer Cells from Human Expanded Potential Stem Cells
Published on: January 13, 2023
Scalable generation of pure CD103+ cDC1 from iDC1 cultures
Insights
Researchers developed a new in vitro system to generate large numbers of pure conventional type 1 dendritic cells (cDC1). This scalable method overcomes limitations in studying cDC1 immunity and developing new immunotherapies.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Conventional type 1 dendritic cells (cDC1) are crucial for immunity against pathogens and tumors.
- cDC1s are rare in vivo, hindering research and therapeutic development.
- Existing methods for generating bone marrow-derived dendritic cells (BMDCs) lack cDC1 selectivity and scalability.
Purpose of the Study:
- To establish a novel in vitro culture system for the selective and scalable generation of cDC1s.
- To characterize the phenotype, function, and developmental requirements of these in vitro-generated cDC1s (iDC1s).
Main Methods:
- Utilized defined media conditions with recombinant FLT3L, GM-CSF, and Kit ligand (KitL) for bone marrow-derived cell culture.
- Performed phenotypic, transcriptional, proteomic, and phospho-proteomic analyses.
- Assessed functional capacity including antigen cross-presentation and cytokine production.
Main Results:
- Successfully generated high-purity ( >95%) CD103+ cDC1s (iDC1s) at a scalable yield (1.5 x 10^9 per mouse).
- iDC1s phenotypically and transcriptionally resembled in vivo cDC1s, distinct from macrophages.
- iDC1s exhibited robust immune functions, including interleukin-12 production and efficient antigen cross-presentation.
- Identified KitL and GM-CSF as key regulators, with GM-CSF suppressing apoptosis and promoting proliferation.
Conclusions:
- The iDC1 culture system provides a scalable platform for cDC1 research.
- This method facilitates mechanistic studies and the development of cDC1-based immunotherapies.
- iDC1s represent a valuable tool for advancing our understanding of cDC1 biology and its therapeutic potential.
Abstract:
Conventional type 1 dendritic cells (cDC1) specialize in cross-presentation and interleukin-12 production and are critical for immunity against intracellular pathogens and tumors, but remain rare in vivo , limiting mechanistic and translational studies. Existing bone marrow-derived dendritic cell (BMDC) methods do not achieve highly selective enrichment of cDC1 or scalable production at high purity. Here, we established a novel in vitro culture system for selective generation of CD103+ cDC1 from mouse bone marrow using defined media conditions together with recombinant FLT3L, GM-CSF, and Kit ligand (KitL), termed iDC1. iDC1 cultures enabled scalable generation of an estimated 1.5 x 10 9 CD103+ cDC1 at greater than 95% purity from a single mouse, representing at least a 75-fold increase relative to previous recombinant cytokine-based methods. Phenotypic and transcriptional analyses demonstrated that iDC1 closely align with the CD103+ cDC1 lineage while remaining clearly distinct from macrophage populations. Functionally, iDC1 responded robustly to innate stimulation, produced interleukin-12 and inflammatory chemokines, and efficiently cross-presented cell-associated antigen to CD8+ T cells. Mechanistically, KitL and GM-CSF regulated distinct stages of cDC1 generation, whereas proteomic, phospho-proteomic, and functional analyses demonstrated that GM-CSF suppresses apoptosis and oxidative stress while promoting cDC1 proliferation. iDC1 generation was dependent on the +32 kb Irf8 enhancer required for bona fide cDC1 development, and STAT5-and BRD4-associated regulatory programs were identified as important regulators of efficient iDC1 generation. Together, these findings establish iDC1 cultures as a scalable platform for studying cDC1 biology and developing cDC1-based immunotherapeutic strategies.
